Drug Topics August 8, 2024
In a clinical trial, IPX203 was able to achieve longer good on-time with less doses compared to standard treatment.
Amneal Pharmaceuticals announced that the FDA has approved its extended-release carbidopa and levodopa (CD/LD, [IPX203]) capsules, marketed as Crexont, for the treatment of Parkinson’s disease, according to a company news release.1
As Parkinson’s disease progresses, patients often experience increased motor fluctuations and reduced “good on-time,” defined as periods without troublesome dyskinesia.1 Whereas existing immediate-release CD/LD products are short-acting, Amneal’s IPX203 combines immediate-release granules and extended-release pellets to provide rapid onset of action and long-lasting efficacy, respectively.
“The approval of Crexont is a seminal moment in the treatment paradigm for PD. The burden of this incurable neurodegenerative disease increases with time....
Today's Sponsors
Today's Sponsor